Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase

NCT07550296 · tracked via the Priya Life Science China tracker

Sponsor

General Hospital of Shenyang Military Region

Phase

Phase 2

Started

2026-05-06

Last updated

2026-06-30

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

prourokinase

prourokinase: Intravenous administration of prourokinase (20 mg infused over a 30-minute period)

Study summary

Ischemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment. Current reperfusion strategies include intravenous thrombolysis (IVT) and endovascular therapy (EVT). Although alteplase is the first-line thrombolytic agent, its recanalization rate for large vessel occlusion (LVO) is only 10-20%, and for medium vessel occlusion (MeVO), approximately 50% of patients fail to achieve recanalization, leading to poor outcomes. Prourokinase has recently been shown to be non-inferior to alteplase with a better safety profile, and studies suggest that repeated thrombolysis may improve recanalization rates in patients without early clinical improvement after standard IVT. Therefore, this study aims to evaluate the efficacy and safety of an additional intravenous infusion of prourokinase in AIS patients with confirmed medium or large vessel occlusion who show no significant clinical improvement at 1 hour after standard IVT (within 4.5 hours of symptom onset). Patients without early neurological improvement (e.g., \<2-point reduction in NIHSS) and persistent vessel occlusion on imaging will receive a second dose of prourokinase. The primary outcomes include 24-hour recanalization rate (by CTA/MRA), 90-day functional outcome (modified Rankin Scale), and safety endpoints (symptomatic intracranial hemorrhage, mortality). The hypothesis is that additional prourokinase following standard IVT in non-improving patients with medium or large vessel occlusion will significantly increase recanalization rates and improve clinical outcomes without an unacceptable increase in symptomatic intracranial hemorrhage.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 year; * Acute ischemic stroke presumably caused by large or medium vessel occlusion within 4.5 hours of onset, having received intravenous thrombolysis of prourokinase, and with no planned thrombectomy; * Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4; * Baseline pc-ASPECTS/ASPECTS ≥ 6, and for posterior circulation infarction, a Pontine-Midbrain Index ≤ 2 (assessed by CT or DWI); * No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis; * Follow-up imaging (CTA or MRA) at 1 hour after the first thrombolysis rules out intracranial hemorrhage and confirms the presence of large or medium vessel occlusion (internal carotid artery, M1-M3 segments of the middle cerebral artery, A1-A3 segments of the anterior cerebral artery, P1-P3 segments of the posterior cerebral artery, basilar artery or V4 segment of the vertebral artery, PICA, AICA, or SCA); * The second intravenous thrombolysis can be administered within 6 hours of onset; * First stroke onset or past stroke without obvious neurological deficit (mRS≤1); * Signed informed consent. Exclusion Criteria: * Planed for endovascular treatment; * Significant white matter hyperintensities (Fazekas score 3); * Any coagulation abnormality before the first thrombolysis, including INR \> 1.5; * Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis.； * Pregnancy； * Allergy to the investigational drug(s)； * Comorbidity with other serious diseases; * Participating in other clinical trials within 3 months; * Patients not suitable for the study considered by researcher.

Primary outcome measure(s)

rate of vessel recanalization — 24 (-6/+12) hours

Trial sites (1)

Facility	City	Region	Status
Hui-Sheng Chen	Shenyang	None Selected	Recruiting

More General Hospital of Shenyang Military Region trials in China

Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease Recruiting

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia Recruiting

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques Recruiting

Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5) Recruiting

Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis Recruiting

Other trials for the same condition

BALANCE Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Recruiting

Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion Recruiting

A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke Starting soon

Fructose for Acute Ischemic Stroke Active, not recruiting

Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07550296 on ClinicalTrials.gov ↗ ← All trials in China